Organic compounds
US9546175B2 · kind B2 · utility
7Cited by
39References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 6, 2015 |
| Grant date | Jan 17, 2017 |
| Priority date | — |
| Expiry date | Aug 6, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K45/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to novel inhibitors of phosphodiesterase 1 (PDE1), useful for the treatment of diseases or disorders characterized by disruption of or damage to certain cGMP/PKG mediated pathways (e.g., in cardiac tissue). The invention further relates to pharmaceutical composition comprising the same and methods of treatment of cardiovascular disease and related disorders, e.g., congestive heart disease, atherosclerosis, myocardial infarction, and stroke.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.